牛牛AI助理已提取核心訊息
180 Life Sciences Corp. has announced the completion of a reverse stock split of its common stock, which was effective on February 28, 2024. The reverse stock split was executed at a ratio of 1-for-19, consolidating every nineteen shares of issued and outstanding common stock into one share. This action was taken to comply with the NASDAQ's minimum bid price requirement for continued listing on the NASDAQ Capital Market. The company's common stock began trading on a post-split basis on February 28, 2024, under the unchanged trading symbols 'ATNF' for common stock and 'ATNFW' for public warrants. The total number of outstanding shares was reduced from approximately 11.3 million to about 0.6 million. The reverse stock split was approved by stockholders on February 16, 2024, and...Show More
180 Life Sciences Corp. has announced the completion of a reverse stock split of its common stock, which was effective on February 28, 2024. The reverse stock split was executed at a ratio of 1-for-19, consolidating every nineteen shares of issued and outstanding common stock into one share. This action was taken to comply with the NASDAQ's minimum bid price requirement for continued listing on the NASDAQ Capital Market. The company's common stock began trading on a post-split basis on February 28, 2024, under the unchanged trading symbols 'ATNF' for common stock and 'ATNFW' for public warrants. The total number of outstanding shares was reduced from approximately 11.3 million to about 0.6 million. The reverse stock split was approved by stockholders on February 16, 2024, and the Board of Directors determined the ratio following the Special Meeting. No fractional shares were issued; instead, stockholders received rounded up whole shares. The reverse stock split did not affect the par value or the voting rights of the common stock. The company's transfer agent, Continental Stock Transfer & Trust Company, is providing instructions to stockholders regarding the reverse stock split. The move aims to increase the closing bid price of the company's common stock to satisfy NASDAQ's minimum bid price requirement, following a deficiency notice received from NASDAQ on September 7, 2023.
180 生命科學公司宣佈完成其普通股的反向股票拆分，該拆分於2024年2月28日生效。反向股票拆分以1比19的比例執行，將每十九股已發行和流通普通股合併爲一股。採取此項行動是爲了遵守納斯達克繼續在納斯達克資本市場上市的最低出價要求。該公司的普通股於2024年2月28日開始在拆分後的基礎上交易，普通股的交易代碼爲 “ATNF”，公共認股權證的交易代碼爲 “ATNFW”。已發行股票總數從約1130萬股減少到約60萬股。股東於 2024 年 2 月 16 日批准了反向股票拆分，董事會在特別會議之後確定了該比例。沒有發行零碎股票；相反，股東收到的股份是四捨五入。反向股票拆分並未影響普通股的面值或投票權。該公司的過戶代理人大陸股票轉讓與信託公司正在向股東提供有關反向股票拆分的指示。在納斯達克於2023年9月7日收到虧損通知後，此舉旨在提高公司普通股的收盤出價，以滿足納斯達克的最低出價要求。
180 生命科學公司宣佈完成其普通股的反向股票拆分，該拆分於2024年2月28日生效。反向股票拆分以1比19的比例執行，將每十九股已發行和流通普通股合併爲一股。採取此項行動是爲了遵守納斯達克繼續在納斯達克資本市場上市的最低出價要求。該公司的普通股於2024年2月28日開始在拆分後的基礎上交易，普通股的交易代碼爲 “ATNF”，公共認股權證的交易代碼爲 “ATNFW”。已發行股票總數從約1130萬股減少到約60萬股。股東於 2024 年 2 月 16 日批准了反向股票拆分，董事會在特別會議之後確定了該比例。沒有發行零碎股票；相反，股東收到的股份是四捨五入。反向股票拆分並未影響普通股的面值或投票權。該公司的過戶代理人大陸股票轉讓與信託公司正在向股東提供有關反向股票拆分的指示。在納斯達克於2023年9月7日收到虧損通知後，此舉旨在提高公司普通股的收盤出價，以滿足納斯達克的最低出價要求。
有用
沒用